Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 4/2006

01.04.2006 | Leading Article

Tailoring Nicotine Replacement Therapy

Rationale and Potential Approaches

verfasst von: Dr Jennifer B. McClure, Gary E. Swan

Erschienen in: CNS Drugs | Ausgabe 4/2006

Einloggen, um Zugang zu erhalten

Abstract

Nicotine replacement therapy (NRT) is an effective treatment for smoking cessation, but as with all such pharmacotherapies, the majority of smokers who use NRT products do not stop smoking or remain abstinent long term. Treatment outcome is affected by a range of individual-specific factors, as well as the pharmacokinetic profile of each NRT formulation. This has led to speculation that abstinence rates could be improved if NRT treatments were individually tailored to best match each individual’s needs and preferences. There are also populations for whom special product and dosage considerations are warranted to maximise treatment safety.
This paper reviews the rationale for NRT treatment, standard dose recommendations and recommendations for how to best match NRT treatment to the specific needs of individual smokers. We also review emerging evidence that genetic profiling may one day be a useful consideration for tailoring NRT treatment.
Fußnoten
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literatur
1.
Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence: clinical practice guidelines. Rockville (MD): United States Department of Health and Human Services. Public Health Service, 2000
2.
3.
Curry SJ, Ludman EJ, McClure J. Self-administered treatment for smoking cessation. J Clin Psychol 2003; 59(3): 305–19PubMedCrossRef
4.
Hays JT, Ebbert JO. Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits. CNS Drugs 2003; 17(2): 71–83PubMedCrossRef
5.
6.
Lancaster T, Stead LF. Self-help interventions for smoking cessation. Cochrane Database Syst Rev 2005; (3): CD001118
7.
Shiffman S, Paty JA, Rohay JM, et al. The efficacy of computer-tailored smoking cessation material as a supplement to nicotine patch therapy. Drug Alcohol Depend 2001; 64(1): 35–46PubMedCrossRef
8.
Strecher VJ. Computer-tailored smoking cessation materials: a review and discussion. Patient Educ Couns 1999; 36(2): 107–17PubMedCrossRef
9.
Stolerman IP, Jarvis MJ. The scientific case that nicotine is addictive. Psychopharmacology 1995; 117(1): 2–10PubMedCrossRef
10.
Benowitz NL, Perez-Stable EJ, Fong I, et al. Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther 1999; 291(3): 1196–203PubMed
11.
Balfour DJ. The neurobiology of tobacco dependence: a commentary. Respiration 2002; 69(1): 7–11PubMedCrossRef
12.
Benowitz NL, Jacob III P, Denaro C, et al. Stable isotope studies of nicotine kinetics and bioavailability. Clin Pharmacol Ther 1991; 49(3): 270–7PubMedCrossRef
13.
Hukkanen J, Jacob III P, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005; 57(1): 79–115PubMedCrossRef
14.
Cummings KM, Hyland A. Impact of nicotine replacement therapy on smoking behavior. Ann Rev Public Health 2005; 26: 583–99CrossRef
15.
Balfour DJ. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens [corrected]. Nicotine Tob Res 2004; 6(6): 899–912PubMedCrossRef
16.
Corrigall WA. Nicotine self-administration in animals as a dependence model. Nicotine Tob Res 1999; 1(1): 11–20PubMedCrossRef
17.
18.
Benowitz NL, Jacob III P. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 1994; 56(5): 483–93PubMedCrossRef
19.
Benowitz NL, Lessov CN, Swan GE, et al. Femaile sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther. In press
20.
Swan GE, Jack LM, Ward MM. Subgroups of smokers with different success rates after use of transdermal nicotine. Addiction 1997; 92(2): 207–17PubMedCrossRef
21.
Perkins KA, Donny E, Caggiula AR. Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob Res 1999; 1(4): 301–15PubMedCrossRef
22.
Benowitz NL, Perez-Stable EJ, Herrera B, et al. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J Natl Cancer Inst 2002; 94(2): 108–15PubMedCrossRef
23.
Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 1997; 282(3): 1608–14PubMed
24.
Nakajima M, Yamamoto T, Nunoya K, et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 1996; 24(11): 1212–7PubMed
25.
Swan GE, Benowitz NL, Lessov CN, et al. Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet Genomics 2005; 15(2): 115–25PubMedCrossRef
26.
Yamazaki H, Inoue K, Hashimoto M, et al. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol 1999; 73(2): 65–70PubMedCrossRef
27.
Caporaso NE, Lerman C, Audrain J, et al. Nicotine metabolism and CYP2D6 phenotype in smokers. Cancer Epidemiol Biomarkers Prev 2001; 10(3): 261–3PubMed
28.
Cholerton S, Arpanahi A, McCracken N, et al. Poor metabolisers of nicotine and CYP2D6 polymorphism. Lancet 1994; 343(8888): 62–3PubMedCrossRef
29.
Le Gal A, Dreano Y, Lucas D, et al. Diversity of selective environmental substrates for human cytochrome P450 2A6: alkoxyethers, nicotine, coumarin, N-nitrosodiethylamine, and N-nitrosobenzylmethylamine. Toxicol Lett 2003; 144(1): 77–91PubMedCrossRef
30.
Bao Z, Su T, Ding X, et al. Metabolism of nicotine and cotinine by human cytochrome P450 2A13 (CYP2A13). 13th International Symposium on Microsomes and Drug Oxidations; 2000 Jul 10–14; Stresa
31.
Cashman JR, Park SB, Berkman CE, et al. Role of hepatic flavin-containing monooxygenase 3 in drug and chemical metabolism in adult humans. Chem Biol Interact 1995; 96(1): 33–46PubMedCrossRef
32.
Nakajima M, Tanaka E, Kwon JT, et al. Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes. Drug Metab Dispos 2002; 30(12): 1484–90PubMedCrossRef
33.
Kuehl GE, Murphy SE. N-glucuronidation of nicotine and cotinine by human liver microsomes and heterologously expressed UDP-glucuronosyltransferases. Drug Metab Dispos 2003; 31(11): 1361–8PubMedCrossRef
34.
Henningfield JE, Fant RV, Buchhalter AR, et al. Pharmacotherapy for nicotine dependence. CA Cancer J Clin 2005; 55(5): 281–99PubMedCrossRef
35.
36.
Hurt RD, Lauger GG, Offord KP, et al. Nicotine-replacement therapy with use of a transdermal nicotine patch: a randomized double-blind placebo-controlled trial. Mayo Clin Proc 1990; 65(12): 1619–23CrossRef
37.
Hughes JR. Pharmacotherapy for smoking cessation: unvalidated assumptions, anomalies, and suggestions for future research. J Consult Clin Psychol 1993; 61(5): 751–60PubMedCrossRef
38.
Henningfield JE, Keenan RM. Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 1993; 61(5): 743–50PubMedCrossRef
39.
Benowitz NL. Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol 1996; 36: 597–613PubMedCrossRef
40.
Paoletti P, Fornai E, Maggiorelli F, et al. Importance of baseline cotinine plasma values in smoking cessation: results from a double-blind study with nicotine patch. Eur Respir J 1996; 9(4): 643–51PubMedCrossRef
41.
Pickworth WB, Fant RV, Butschky MF, et al. Effects of transdermal nicotine delivery on measures of acute nicotine withdrawal. J Pharmacol Exp Ther 1996; 279(2): 450–6PubMed
42.
Schneider NG, Olmstead R, Mody FV, et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction 1995; 90(12): 1671–82PubMedCrossRef
43.
Hjalmarson A, Franzon M, Westin A, et al. Effect of nicotine nasal spray on smoking cessation. Arch Intern Med 1994; 154: 2567–72PubMedCrossRef
44.
Schneider NG, Lunell E, Olmstead RE, et al. Clinical pharmacokinetics of nasal nicotine delivery: a review and comparison to other nicotine systems. Clin Pharmacokinet 1996; 31(1): 65–80PubMedCrossRef
45.
Schuh KJ, Schuh LM, Henningfield JE, et al. Nicotine nasal spray and vapor inhaler: abuse liability assessment. Psychopharmacology 1997; 130(4): 352–61PubMedCrossRef
46.
Hajek P, West R, Foulds J, et al. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 1999; 159(17): 2033–8PubMedCrossRef
47.
Choi JH, Dresler CM, Norton MR, et al. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 2003; 5(5): 635–44PubMedCrossRef
48.
Glover ED, Glover PN, Franzon M, et al. A comparison of a nicotine sublingual tablet and placebo for smoking cessation. Nicotine Tob Res 2002; 4(4): 441–50PubMedCrossRef
49.
Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004; (3): CD000146
50.
Fagerstrom KO, Tejding R, Westin A, et al. Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker? Tob Control 1997; 6(4): 311–6PubMedCrossRef
51.
West R, Hajek P, Nilsson F, et al. Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacology 2001; 153(2): 225–30PubMedCrossRef
52.
Haustein KO. What can we do in secondary prevention of cigarette smoking? Eur J Cardiovasc Prev Rehabil 2003; 10(6): 476–85PubMedCrossRef
53.
Hurt RD, Dale LC, Fredrickson PA, et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. JAMA 1994; 271: 595–600PubMedCrossRef
54.
Dale LC, Hurt RD, Offord KP, et al. High-dose nicotine patch therapy: percentage of replacement and smoking cessation. JAMA 1995; 274(17): 1353–8PubMedCrossRef
55.
Fredrickson PA, Hurt RD, Lee GM, et al. High dose transdermal nicotine therapy for heavy smokers: safety, tolerability and measurement of nicotine and cotinine levels. Psychopharmacology 1995; 122(3): 215–22PubMedCrossRef
56.
Jorenby DE, Smith SS, Fiore MC, et al. Varying nicotine patch dose and type of smoking cessation counseling. JAMA 1995; 274(17): 1347–52PubMedCrossRef
57.
Hughes JR, Lesmes GR, Hatsukami DK, et al. Are higher doses of nicotine replacement more effective for smoking cessation? Nicot Tob Res 1999; 1(2): 169–74CrossRef
58.
Killen JD, Fortmann SP, Davis L, et al. Do heavy smokers benefit from higher dose nicotine patch therapy? Exp Clin Psychopharmacol 1999; 7(3): 226–33PubMedCrossRef
59.
Tonnesen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J 1999; 13(2): 238–46
60.
Blondal T, Gudmundsson LJ, Olafsdottir I, et al. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. BMJ 1999; 318(7179): 285–8PubMedCrossRef
61.
Bohadana A, Nilsson F, Rasmussen T, et al. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2000; 160(20): 3128–34PubMedCrossRef
62.
Kornitzer M, Boutsen M, Dramaix M, et al. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med 1995; 24(1): 41–7PubMedCrossRef
63.
Puska P, Korhonen HJ, Vartiainen E, et al. Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. Tob Control 1995; 4: 231–5CrossRef
64.
Tonnesen P, Mikkelsen KL. Smoking cessation with four nicotine replacement regimes in a lung clinic. Eur Respir J 2000; 16(4): 717–22PubMedCrossRef
65.
Croghan GA, Sloan JA, Croghan IT, et al. Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. Nicotine Tob Res 2003; 5(2): 181–7PubMedCrossRef
66.
Hand S, Edwards S, Campbell IA, et al. Controlled trial of three weeks nicotine replacement treatment in hospital patients also given advice and support. Thorax 2002; 57(8): 715–8PubMedCrossRef
67.
Sweeney CT, Fant RV, Fagerstrom KO, et al. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs 2001; 15(6): 453–67PubMedCrossRef
68.
West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax. 2000; 55(12): 987–99PubMedCrossRef
69.
Fiore MC, Smith SS, Jorenby DE, et al. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA 1994; 271(24): 1940–7PubMedCrossRef
70.
Bolin LJ, Antonuccio DO, Follette WC, et al. Transdermal nicotine: the long and the short of it. Psychol Addict Behav 1999; 13: 152–6CrossRef
71.
Stapleton JA, Russell MA, Feyerabend C, et al. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction 1995; 90(1): 31–42PubMedCrossRef
72.
Pomerleau OF, Pomerleau CS, Marks JL, et al. Prolonged nicotine patch use in quitters with past abstinence-induced depressed mood. J Subst Abuse Treat 2003; 24(1): 13–8PubMedCrossRef
73.
Medioni J, Berlin I, Mallet A. Increased risk of relapse after stopping nicotine replacement therapies: a mathematical modelling approach. Addiction 2005; 100(2): 247–54PubMedCrossRef
74.
Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340(9): 685–91PubMedCrossRef
75.
Killen JD, Robinson TN, Ammerman S, et al. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J Consult Clin Psychol 2004; 72(4): 729–35PubMedCrossRef
76.
Ford CL, Zlabek JA. Nicotine replacement therapy and cardiovascular disease. Mayo Clin Proc 2005; 80(5): 652–6PubMedCrossRef
77.
Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease. Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med 1994; 154(9): 989–95CrossRef
78.
Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 335(24): 1792–8PubMedCrossRef
79.
Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf 1998; 18(4): 297–308PubMedCrossRef
80.
Kimmel SE, Berlin JA, Miles C, et al. Risk of acute first myocardial infarction and use of nicotine patches in a general population. J Am Coll Cardiol 2001; 37(5): 1297–302PubMedCrossRef
81.
Ludvig J, Miner B, Eisenberg MJ. Smoking cessation in patients with coronary artery disease. Am Heart J 2005; 149(4): 565–72PubMedCrossRef
82.
83.
Dempsey DA, Benowitz NL. Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf 2001; 24(4): 277–322PubMedCrossRef
84.
Coleman T, Antoniak M, Britton J, et al. Recruiting pregnant smokers for a placebo-randomised controlled trial of nicotine replacement therapy. BMC Health Serv Res 2004; 4(1): 29PubMedCrossRef
85.
Hurt RD, Croghan GA, Beede SD, et al. Nicotine patch therapy in 101 adolescent smokers: efficacy, withdrawal symptom relief, and carbon monoxide and plasma cotinine levels. Arch Pediatr Adolesc Med 2000; 154(1): 31–7PubMed
86.
Smith TA, House Jr RF, Croghan IT, et al. Nicotine patch therapy in adolescent smokers. Pediatrics 1996; 98 (4 Pt 1): 659–67PubMed
87.
Hanson K, Allen S, Jensen S, et al. Treatment of adolescent smokers with the nicotine patch. Nicotine Tob Res 2003; 5(4): 515–26PubMed
88.
Moolchan ET, Robinson ML, Ernst M, et al. Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction. Pediatrics 2005; 115(4): E407–14PubMedCrossRef
89.
American Psychiatric Association. Practice guideline for the treatment of patients with nicotine dependence. Am J Psychiatry 1996; 153(10 Suppl.): 1–31
90.
Abrams DB, Niaura R, Brown RA, et al. The tobacco dependence treatment handbook: a guide to best practices. New York: The Guilford Press, 2003
91.
Johnstone EC, Yudkin PL, Hey K, et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 2004; 14(2): 83–90PubMedCrossRef
92.
Yudkin P, Munafo M, Hey K, et al. Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ 2004; 328(7446): 989–90PubMedCrossRef
93.
Lerman C, Wileyto EP, Patterson F, et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 2004; 4(3): 184–92PubMedCrossRef
94.
95.
Lerman C, Shields PG, Wileyto EP, et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 2003; 22(5): 541–8PubMedCrossRef
96.
Swan GE, Jack LM, Curry SJ, et al. Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. Health Psychol. In press
97.
Cardon LR, Idury RM, Harris TJ, et al. Testing drug response in the presence of genetic information: sampling issues for clinical trials. Pharmacogenetics 2000 Aug; 10(6): 503–10PubMedCrossRef
98.
Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286(5439): 487–91PubMedCrossRef
99.
Flowers CR, Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 2004; 22(8): 481–93PubMedCrossRef
100.
Xu C, Goodz S, Sellers EM, et al. CYP2A6 genetic variation and potential consequences. Adv Drug Deliv Rev 2002; 54(10): 1245–56PubMedCrossRef
Metadaten
Titel
Tailoring Nicotine Replacement Therapy
Rationale and Potential Approaches
verfasst von
Dr Jennifer B. McClure
Gary E. Swan
Publikationsdatum
01.04.2006
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 4/2006
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200620040-00002

Weitere Artikel der Ausgabe 4/2006

CNS Drugs 4/2006 Zur Ausgabe

Therapy in Practice

Long-Term Prophylaxis in Bipolar Disorder

Commentary

The SOHO (Schizophrenia Outpatient Health Outcome) Study

Correspondence

Reports of Acute Angle Closure Glaucoma-Related Adverse Events with SSRIs: Results of a Disproportionality Analysis

Leading Article

Aromatherapy in the Management of Psychiatric Disorders

Adis Drug Profile

Ziconotide

Adis Drug Profile

Ziconotide

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise